IDSA: Experimental Rx May Be Option in Drug-Resistant HIV

This article originally appeared here.
Share this content:
IDSA: Experimental Rx May Be Option in Drug-Resistant HIV
IDSA: Experimental Rx May Be Option in Drug-Resistant HIV

FRIDAY, Oct. 28, 2016 (HealthDay News) -- The intravenous drug ibalizumab might revolutionize the treatment of HIV patients who don't respond to existing drugs, according to research presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 26 to 30 in New Orleans.

The study authors tested the drug in 40 patients with multi-drug-resistant HIV in this phase 3 study. The patients had been infected with HIV for an average of 21 years.

The researchers found that after seven days, 83 percent of patients showed a significant response. No treatment-related serious adverse events or discontinuations were reported during this time period.

Study author Jacob Lalezari, M.D., an assistant clinical professor of medicine at the University of California, San Francisco, and medical director for Quest Clinical Research, told HealthDay that this drug offered a "double return": It will also potentially prevent treated patients from transmitting the virus to other people, he said.

The study was funded by TaiMed Biologics, the manufacturer of ibalizumab. The research team included employees of the company.

Abstract
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Progress Made on Genetic Test for Anal Cancer

Progress Made on Genetic Test for Anal Cancer

But research is still in early stages

Four Separate Events Led to Zika's Introduction Into Florida

Four Separate Events Led to Zika's Introduction Into ...

Virus strains came from the Caribbean and Latin America, researchers say

New Health Care Act Could Result in 23 Million Losing Insurance

New Health Care Act Could Result in 23 ...

While premiums may lower over the long-term, many would face much higher out-of-pocket costs

is free, fast, and customized just for you!

Already a member?

Sign In Now »